Tranexamic acid in remote damage control resuscitation

Transfusion

Volumn 53, Issue SUPPL. 1, 2013, Pages

  Rappold, Joseph F ^a,b   Pusateri, Anthony E ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; TRANEXAMIC ACID;

BLEEDING; BLOOD COMPONENT THERAPY; HUMAN; INJURY; METHODOLOGY; RESUSCITATION; REVIEW;

ANTIFIBRINOLYTIC AGENTS; BLOOD COMPONENT TRANSFUSION; HEMORRHAGE; HUMANS; RESUSCITATION; TRANEXAMIC ACID; WOUNDS AND INJURIES;

MLCS; MLOWN;

EID: 84874807138     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12042     Document Type: Article

References (20)

1. Ide M, Bolliger D, Taketomi T, Tanaka K. Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery. J Anesth 2010;24:96-106.
2. Chang M, Kistler EB, Schmid-Schönbein GW. Disruption of the mucosal barrier during gut ischemia allows entry of digestive enzymes into the intestinal wall. Shock 2012;37: 297-305.
3. Jiménez JJ, Iribarren JL, Brouard M, Hernández D, Palmero S, Jiménez A, Lorente L, Machado P, Borreguero JM, Raya JM, Martín B, Pérez R, Martínez R, Mora ML. Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized doubleblind, dose-dependent, phase IV clinical trial. J Cardiothorac Surg 2011;6:138.
4. Reichel CA, Lerchenberger M, Uhl B, Rehberg M, Berberich N, Zahler S, Wymann MP, Krombach F. Plasmin inhibitors prevent leukocyte accumulation and remodeling events in the postischemic microvasculature. PLoS One 2011;6: e17229.
5. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008;107:1783-90.
6. Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 2009;180:183-93.
7. Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res 2009; 123:687-96.
8. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care 2010;14:R148.
9. Martin K, Knorr J, Breuer T, Gertler R, Macguill M, Lange R, Tassani P, Wiesner G. Seizures after open heart surgery: comparison of epsilon-aminocaproic acid and tranexamic acid. J Cardiothorac Vasc Anesth 2011;25:20-5.
10. Shakur H, Roberts R, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Yutthakasemsunt S, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23-32.
11. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011;377:1096-101, 1101 e1-2.
12. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) study. Arch Surg 2012;147:113-9.
13. Furtmuller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, Redl H. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gammaaminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther 2002;301:168-73.
14. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010;110:350-3.
15. Koster A, Börgermann J, Zittermann A, Lueth JU, Gillis-Januszewski T, Schirmer U. Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome. Br J Anaesth 2012 [Epub ahead of print].
16. Levi M. Should anifibrinolytics be given in all patients with trauma? Curr Opin Anaesthesiol 2012;25:385-8.
17. Callum JL, Rizoli S. Plasma transfusion for patients with severe hemorrhage: what is the evidence? Transfusion 2012;52:30S-7S.
18. US Army Institute for Surgical Research. Clinical practice guideline for damage control resuscitation. 2012. [cited 2012 Dec 4]. Available from: URL: http://www.usaisr.amedd.army.mil/assets/cpgs/Damage-Control-Resuscitation-11- Oct%202012.pdf
19. Committee on Tactical Combat Casualty Care. Military prehospital life support course 2012, tactical combat casualty care guidelines. [cited 2012 Dec 4]. Available from: URL: http://www.health.mil/Education-And-Training/ TCCC.aspx
20. Gong H, Wang W, Kwon TH, Jonassen T, Frøkiaer J, Nielsen S. Reduced renal expression of AQP2, p-AQP2 and AQP3 in haemorrhagic shock-induced acute renal failure. Nephrol Dial Transplant 2003;18:2551-9.